Dimerix Ltd Sustainability Reports
Dimerix Limited operates as a clinical-stage biopharmaceutical company that develops and commercializes pharmaceutical products for patients with inflammatory diseases. Its primary asset is QYTOVRA (DMX-200), which is undergoing late-stage clinical testing for the treatment of focal segmental glomerulosclerosis, a rare kidney disease.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
FIGI: BBG001S9Z6Y8
10 reports from 2016 to 2026
